Literature DB >> 11341670

Reversible pheripheral edema in female patients taking proton pump inhibitors for peptic acid diseases.

G Brunner1, C Athmann, J H Boldt.   

Abstract

Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses. Edema disappeared two to three days after stopping therapy but reappeared in all five patients after being reexposed to the drugs. In three of the patients drug kinetic investigations were performed and revealed a slow metabolizer status. During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid. The edema disappeared within 24 hr after stopping the infusion therapy. Serum hormone concentrations in these patients did not change during therapy, neither did the edema factor C1-esterase inhibitor. As a possible mechanism, a competitive inhibition at the receptor site of female hormones involved in water regulation is suspected.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11341670     DOI: 10.1023/a:1010745624971

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  17 in total

1.  Omeprazole provides quicker symptom relief and duodenal ulcer healing than ranitidine.

Authors:  R J McFarland; M C Bateson; J R Green; D P O'Donoghue; M W Dronfield; P W Keeling; G J Burke; R J Dickinson; D R Shreeve; E M Peers
Journal:  Gastroenterology       Date:  1990-02       Impact factor: 22.682

Review 2.  Drugs for pH control in upper gastrointestinal bleeding.

Authors:  G Brunner; P Luna; C Thiesemann
Journal:  Aliment Pharmacol Ther       Date:  1995       Impact factor: 8.171

3.  Efficacy and safety of omeprazole in the long-term treatment of peptic ulcer and reflux oesophagitis resistant to ranitidine.

Authors:  G H Brunner; R Lamberts; W Creutzfeldt
Journal:  Digestion       Date:  1990       Impact factor: 3.216

4.  High-performance liquid chromatographic determination of the H+/K+ ATPase inhibitor (BY 1023/SK&F 96,022) and its sulphone metabolite in serum or plasma by direct injection and fully automated pre-column sample clean-up.

Authors:  R Huber; W Müller; M C Banks; S J Rogers; P C Norwood; E Doyle
Journal:  J Chromatogr       Date:  1990-08-03

5.  An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment.

Authors:  G Brunner; R Arnold; U Hennig; W Fuchs
Journal:  Aliment Pharmacol Ther       Date:  1993       Impact factor: 8.171

6.  Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis.

Authors:  R Lamberts; W Creutzfeldt; H G Strüber; G Brunner; E Solcia
Journal:  Gastroenterology       Date:  1993-05       Impact factor: 22.682

7.  Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing?

Authors:  H S Merki; C H Wilder-Smith
Journal:  Gastroenterology       Date:  1994-01       Impact factor: 22.682

8.  Appropriate acid suppression for the management of gastro-oesophageal reflux disease.

Authors:  N J Bell; D Burget; C W Howden; J Wilkinson; R H Hunt
Journal:  Digestion       Date:  1992       Impact factor: 3.216

9.  Omeprazole for peptic ulcer disease in pregnancy.

Authors:  G Brunner; H Meyer; C Athmann
Journal:  Digestion       Date:  1998 Nov-Dec       Impact factor: 3.216

10.  A double-blind study of pantoprazole and ranitidine in treatment of acute duodenal ulcer. A multicenter trial. European Pantoprazole Study Group.

Authors:  M Cremer; R Lambert; C B Lamers; G Delle Fave; C Maier
Journal:  Dig Dis Sci       Date:  1995-06       Impact factor: 3.199

View more
  5 in total

1.  Reversible edema in a male patient taking parenteral pantoprazole infusion for pyloric stenosis.

Authors:  Engin Sennaroglu; Sebnem Karakan; Mansur Kayatas; Saadet Akdur; Hulki Genc; Tarkan Karakan; Rifki Ucler; Cem Ozisler; Yuksel Urun
Journal:  Dig Dis Sci       Date:  2006-01       Impact factor: 3.199

2.  Proton pump inhibitors: use, misuse and concerns about long-term therapy.

Authors:  T P Rakesh
Journal:  Clin J Gastroenterol       Date:  2011-02-18

3.  Liver hepatotoxicity associated with pantoprazole: a rare case report.

Authors:  Mehmet Aslan; Yilmaz Celik; Sevdegul Karadas; Sehmus Olmez; Adem Cifci
Journal:  Wien Klin Wochenschr       Date:  2014-03-21       Impact factor: 1.704

4.  Transmucosal gastric leak induced by proton pump inhibitors.

Authors:  Lisa J Murray; Melissa Gabello; David S Rudolph; Christopher P Farrell; Melissa Morgan; Aaron P Martin; James C Underwood; M Carmen Valenzano; James M Mullin
Journal:  Dig Dis Sci       Date:  2008-11-18       Impact factor: 3.199

5.  Pharmacokinetics and Tissue Levels of Pantoprazole in Neonatal Calves After Intravenous Administration.

Authors:  Jeff D Olivarez; Amanda J Kreuder; Dane M Tatarniuk; Larry W Wulf; Katarzyna A Dembek; Jonathan P Mochel; Joe S Smith
Journal:  Front Vet Sci       Date:  2020-11-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.